Eli Lilly And Co (NYSE:LLY) Shares Sold by Harbour Capital Advisors LLC

Harbour Capital Advisors LLC trimmed its holdings in Eli Lilly And Co (NYSE:LLY) by 1.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 22,574 shares of the company’s stock after selling 343 shares during the period. Eli Lilly And Co accounts for about 1.1% of Harbour Capital Advisors LLC’s investment portfolio, making the stock its 23rd largest position. Harbour Capital Advisors LLC’s holdings in Eli Lilly And Co were worth $2,967,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of LLY. Voya Financial Advisors Inc. lifted its holdings in shares of Eli Lilly And Co by 14.4% during the 3rd quarter. Voya Financial Advisors Inc. now owns 13,059 shares of the company’s stock worth $1,467,000 after acquiring an additional 1,640 shares during the period. Tokio Marine Asset Management Co. Ltd. lifted its holdings in shares of Eli Lilly And Co by 5.8% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,285 shares of the company’s stock worth $479,000 after acquiring an additional 233 shares during the period. Norway Savings Bank lifted its holdings in shares of Eli Lilly And Co by 8.7% during the 3rd quarter. Norway Savings Bank now owns 6,912 shares of the company’s stock worth $773,000 after acquiring an additional 555 shares during the period. Integrated Wealth Concepts LLC raised its holdings in Eli Lilly And Co by 4.4% in the third quarter. Integrated Wealth Concepts LLC now owns 4,108 shares of the company’s stock valued at $459,000 after buying an additional 174 shares during the period. Finally, Windsor Group LTD raised its holdings in Eli Lilly And Co by 2.0% in the fourth quarter. Windsor Group LTD now owns 65,802 shares of the company’s stock valued at $8,648,000 after buying an additional 1,316 shares during the period. 76.27% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly And Co stock traded up $0.65 during mid-day trading on Wednesday, reaching $141.56. The company’s stock had a trading volume of 2,741,169 shares, compared to its average volume of 3,756,555. The firm has a market cap of $134.02 billion, a price-to-earnings ratio of 17.22, a PEG ratio of 1.82 and a beta of 0.20. The business has a 50 day moving average price of $130.86 and a 200-day moving average price of $116.40. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 4.09. Eli Lilly And Co has a twelve month low of $101.36 and a twelve month high of $142.25.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 23rd. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.05. The firm had revenue of $5.48 billion during the quarter, compared to the consensus estimate of $5.50 billion. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The firm’s revenue was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.39 earnings per share. On average, equities analysts expect that Eli Lilly And Co will post 5.8 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 14th will be issued a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a yield of 2.09%. The ex-dividend date of this dividend is Thursday, February 13th. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.65. Eli Lilly And Co’s payout ratio is currently 46.49%.

Several research firms recently commented on LLY. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly And Co from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, December 18th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $143.00 price objective on shares of Eli Lilly And Co in a research report on Monday, December 2nd. Morgan Stanley raised shares of Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $116.00 to $150.00 in a research report on Wednesday, December 18th. They noted that the move was a valuation call. UBS Group lowered their price objective on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research report on Thursday, October 17th. Finally, Argus raised their price target on shares of Eli Lilly And Co from $145.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, December 30th. Five investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Eli Lilly And Co presently has a consensus rating of “Buy” and a consensus price target of $135.67.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly And Co stock in a transaction on Monday, January 13th. The shares were sold at an average price of $138.92, for a total value of $28,478,600.00. Following the completion of the transaction, the insider now owns 113,741,549 shares of the company’s stock, valued at $15,800,975,987.08. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Anne E. White acquired 1,000 shares of the firm’s stock in a transaction on Friday, October 25th. The stock was acquired at an average cost of $108.84 per share, with a total value of $108,840.00. Following the acquisition, the senior vice president now owns 22,043 shares of the company’s stock, valued at $2,399,160.12. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 8,405 shares of company stock valued at $909,004 and sold 1,780,504 shares valued at $219,697,912. Insiders own 0.11% of the company’s stock.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: Why Invest in Dividend Achievers?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.